Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 30, 2009

Proximagen Takes Over Biovitrum’s Drug Discovery Subsidiary and Certain CNS Candidates

  • Proximagen Neuroscience is to acquire Biovitrum’s wholly owned drug discovery subsidiary, Cambridge Biotechnology (CBT), together with a number of Biovitrum’s drug development programs. These include the company’s clinical-stage 5-HT2c agonist and cognitive 5-HT6 central nervous system programs along with its preclinical VAP-1 and TrkA compounds.

    CBT was spun out of Biovitrum in January and had unaudited net assets of £109,000, or about $179,908, as of the end of September. Proximagen is acquiring CBT on a cash-free/debt-free basis and will pay Biovitrum a percentage of future revenues from the acquired assets. The company claims this deal structure means risks are minimized as it will only need to make payments when the drugs generate earnings.

    Proximagen also maintains the acquisition is in line with its strategy to acquire later-stage drug candidates. To this end, the firm completed a £50 million (roughly $82.53 million) fundraising in June.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »